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Abstract
An ever increasing number of patients with neurodegen-
erative disorders calls for the evaluation of potential
diagnostic markers that allow an early diagnosis and an
early initiation of specific therapy. Clinical diagnosis of
Alzheimer’s disease (AD), the most common neurode-
generative disorder, reaches 80–90% accuracy upon au-
topsy in specialized clinical centers. Diagnosis of AD in
early clinical or preclinical stages is far less accurate, as
is the differential diagnosis between AD and other prima-
ry dementias, such as frontotemporal dementia (FTD).
Microtubule-associated tau protein is abnormally phos-
phorylated in AD and aggregates as paired helical fila-
ments in neurofibrillary tangles. Recently, immunoas-
says have been developed detecting tau phosphorylated
at specific epitopes in cerebrospinal fluid (CSF). Four
years of clinical research consistently demonstrate that
CSF phosphorylated tau (p-tau) is highly increased in AD
compared to healthy controls and may differentiate AD
from its most relevant differential diagnoses. Tau phos-
phorylated at threonine 231 (p-tau231) shows excellent
differentiation between AD and FTD, whereas serine 181
(p-tau181) enhances accurate differentiation between AD
and dementia with Lewy bodies. Moreover, p-tau231 lev-
els decline with disease progression, correlating with
cognitive performance at baseline. Total tau (t-tau) is
regarded as a general marker of neurodegeneration for
evaluation in future population-based studies. p-tau231
and p-tau181 yield excellent discrimination between AD
and non-AD dementias including FTD, exceeding the dif-
ferential diagnostic and prognostic accuracy of t-tau.
Therefore, p-tau is a core biological marker candidate for
future evaluation in large national and international mul-
ticenter networks.
Copyright © 2004 S. Karger AG, Basel
Development of Biological Markers for
Frontotemporal Dementia
The clinical entity of frontotemporal dementia (FTD)
is believed to represent a wide range of neuropathological
conditions. Most of the heterogeneous clinical presenta-
tions of FTD show pathological changes of the microtu-
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bule-associated tau protein. Tau gene mutations have
been identified in familial FTD cases. Even in many spo-
radic FTD cases without detectable tau gene mutations,
abnormal phosphorylation of microtubule-associated tau
occurs as well.
Microtubule-associated tau protein is elevated in cere-
brospinal fluid (CSF) in a wide range of acute or chronic
conditions of neuron loss, like stroke, head trauma,
Creutzfeldt-Jacob disease, and neurodegenerative disor-
ders like FTD and AD. Therefore, tau protein in CSF is
thought to be an unspecific marker of neuronal degenera-
tion. It was expected that measurement of tau protein in
CSF may help to distinguish early stages of FTD and AD
from healthy aging. In contrast, the value of CSF tau pro-
tein for the distinction between FTD and other neurode-
generative disorders may be limited.
In the past 10 years, assays have been developed to
detect specific abnormal phosphorylation sites of CSF
tau, and have recently been applied to a range of neurode-
generative disorders. These assays had primarily been
developed to capture the specific pattern of abnormal
phosphorylation of tau protein in AD, but these newly
established markers may be useful in the diagnosis of
FTD as well. Because abnormal phosphorylation of tau
proteins is a common pathway in the development of neu-
rodegenerative disorders and different neurodegenerative
disorders are believed to exhibit a distinctive pattern of
tau protein phosphorylation sites, it was expected that
measurement of specific phosphorylation epitopes of tau
proteins in CSF may increase the accuracy of CSF tau to
discriminate neurodegenerative disorders from healthy
aging, but also to more accurately differentiate between
different neurodegenerative disorders.
A future biomarker of FTD or any other neurodegener-
ative disorder will have to meet specific criteria. The ideal
biomarker should detect a fundamental feature of neuro-
pathology and be validated in neuropathologically con-
firmed cases; it should have a high diagnostic sensitivity
and specificity, it should be reliable, reproducible, nonin-
vasive, simple to perform, and inexpensive. Recom-
mended steps to establish a biomarker include confirma-
tion by at least two independent studies conducted by
qualified investigators, with the results published in peer-
reviewed journals [1]. Beyond these criteria for early and
accurate diagnosis, the biomarker should also capture the
beneficial effect of disease-modifying therapy. We need to
be able to make accurate diagnoses early in the disease
process and we need to be able to evaluate, effectively and
inexpensively, whether treatments are working.
Because of the high prevalence of AD and the overlap-
ping symptoms of AD and FTD, the decisive clinical use
of any future FTD biomarker will be the separation of
FTD from AD and other neurodegenerative disorders
rather than the discrimination between FTD and healthy
aging.
Tau Proteins
Normally, the 6 hyperphosphorylated brain tau iso-
forms (PHF-tau) are located mainly in axons, associated
with the cytoskeleton and intracellular transport systems.
Total tau (t-tau) and truncated forms of monomeric and
phosphorylated tau (p-tau) can be measured in CSF.
Using antibodies that detect all isoforms of tau proteins
independent of phosphorylation or specific phosphoryla-
tion sites, ELISAs have been developed to measure t-tau
and specifically phosphorylated CSF tau protein (p-tau)
concentrations [2, 3].
Total Tau
The level of CSF tau probably reflects the general
degree of neuronal degeneration and damage. This notion
is supported by the finding that a marked transient
increase in CSF tau is found after acute stroke, with a pos-
itive correlation between CSF tau and infarct size mea-
sured by CT [4]. Further, the degree of increase in CSF
t-tau is higher in disorders with more extensive and/or
rapid neuronal degeneration. A very marked increase is
found in Creutzfeldt-Jacob disease, with very rapid de-
generation [5] and a moderate increase is found in AD,
with widespread degeneration [6, 7].
In FTD, increased tau levels compared to healthy
aging have been found by some investigators [8–10],
while not in other studies [7, 11]. Diagnostic sensitivity of
tau protein classifying FTD patients and healthy subjects
reached about 82–85% in those studies where tau protein
was found elevated [12]. Tau levels in FTD compared to
AD (fig. 1) have been found reduced, but the diagnostic
value of tau for separation between FTD and AD is lim-
ited, with the sensitivity and specificity levels yielding 81
and 65%, respectively [13].
The most consistent and widely established finding is a
statistically significant increase in CSF t-tau protein in
AD [2, 3]. Applying appropriate statistical methods, such
as multivariate discriminant analysis, combination of t-
tau with other pathophysiologically relevant marker can-
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didates may increase diagnostic accuracy compared to a
single marker.
Because of its nature as an indicator of neuronal degen-
eration, elevated CSF t-tau is found in a wide proportion
of cases with primary and secondary dementia disorders
other than FTD or AD. In contrast, in patients with other
types of dementias (e.g. alcoholic dementia), chronic neu-
rological disorders (e.g. Parkinson’s disease, progressive
supranuclear palsy) and psychiatric disorders (e.g. depres-
sion), elevated CSF tau levels are found only in few cases
[6, 10].
In summary, tau protein is of limited value in the dis-
crimination of FTD from healthy aging and AD in some,
but not all studies. One reason for the conflicting results in
different studies may be the pathological heterogeneity of
clinical cases with FTD. Tau levels may differ between
different subtypes of FTD. Therefore, it is necessary to
study clinical, and ideally pathological, subtypes of FTD
to evaluate a potential use of tau proteins in the differ-
ential diagnosis of FTD.
Biochemical analyses of tau protein abnormalities in
postmortem studies have been reported [14]. Fractiona-
tion of tau protein differentiates disorders with and with-
out measurable amounts of insoluble tau. Further charac-
terization of this abnormal insoluble tau differentiates
cases with a predominance of tau with 3 microtubule-
binding repeats, 4 microtubule-binding repeats, or a com-
bination of both [15, 16]. One investigation has also sug-
gested that some frontotemporal degenerative disorders
have a marked reduction of all soluble fraction tau pro-
teins with preserved levels of tau messenger RNA [17].
These results suggest that the analysis of soluble tau iso-
form may be useful in characterizing frontotemporal de-
generative disorders.
Phosphorylated Tau 
Currently, promising efforts are under way to establish
p-tau in CSF as a putative disease-specific biological
marker for AD. Immunoassays have been developed to
specifically detect tau at different epitopes, such as
threonine 231 (p-tau231), serine 199 (p-tau199) and threon-
ine 181 (p-tau181) [2, 3]. Evidence from these studies indi-
cates that quantification of tau phosphorylated at these
specific sites may improve early detection, differential
diagnosis and tracking of disease progression in AD. p-tau
assays have been studied so far in several hundred AD
patients and healthy subjects, as well as patient samples
with other neurodegenerative disorders and vascular de-
Fig. 1. CSF levels of t-tau in AD patients and FTD patients.
mentia over the past 4 years. In contrast, no assays have
been developed to detect characteristic tau phosphoryla-
tion sites in FTD.
In a large-scale multicenter study, the levels of p-tau231
were significantly increased in AD compared to FTD
patients (fig. 2). Moreover, p-tau231 compared to t-tau
raised sensitivity levels in the discrimination of AD and
FTD from 57.7 to 90.2% at a specificity level of 92.3% for
both markers (fig. 3) [13]. In a multicenter study designed
to provide evidence for the selection of p-tau231, p-tau181,
and p-tau199 bioassays for AD in larger-scale international
dementia networks, p-tau231 maximized group separation
between FTD and AD compared with the other p-tau
assays, reaching a sensitivity of 92%, when specificity was
set at 85% [18]. For comparison, p-tau181 and p-tau199
reached sensitivity levels between 42 and 79% for the
detection of FTD, when specificity was set at 85%.
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Fig. 2. CSF levels of p-tau231 in AD patients and FTD patients.
Fig. 3. Receiver operating characteristics (ROC) curve analysis for
the discrimination of 80 AD and 26 FTD patients by t-tau and p-
tau231. The area under the ROC curve (AUC) represents the proba-
bility to correctly allocate a patient into the AD or FTD group, given
the subject’s CSF t-tau or p-tau231 concentration. AUC was signifi-
cantly higher for p-tau231 than for t-tau (p ! 0.05).
Conclusions
The utility of t-tau in the differentiation of FTD from
healthy aging is not yet clear. The heterogeneity of clinical
FTD with respect to the underlying tau pathology very
likely contributes to the conflicting findings on CSF tau
elevations in FTD. Future studies may reveal certain
pathological subtypes of FTD which can be distinguished
from healthy subjects by the measurement of t-tau or tau
phosphorylation epitopes. This would bear relevance both
for the diagnosis of FTD and for the prognosis and treat-
ment of different subtypes of FTD.
The separation of FTD and AD by t-tau is not suffi-
cient, with sensitivity and specificity levels far below
80%. Much more promising in this respect is the detec-
tion of specific tau phosphorylation epitopes in CSF. The
most extensively studied epitopes are p-tau231 and p-
tau181. For p-tau231, recent multicenter studies suggest a
correct allocation of FTD and AD patients with an accu-
racy above 80%. The role of p-tau as a biomarker for
FTD, however, appears to be limited to the distinction
from AD. The separation of FTD from healthy aging and
other types of dementias is far below a correct classifica-
tion rate of 80%. Recent postmortem examinations have
suggested a specific fingerprint of tau phosphorylation
and fractionation in FTD that may prove useful as a bio-
marker of FTD in the future.
The development of a biological marker for the diagno-
sis of disease can be conceptualized in three subsequent
steps [19]. The first step is the technical and methodologi-
cal development of the marker, including the establish-
ment of assay variance, test-retest variability, and the
technical feasibility of the marker. The second step is the
evaluation of the marker in selected patient samples. This
step serves to estimate sensitivity and specificity of a
marker. The third step is the evaluation of the marker in a
clinical setting, where the population is not selected
according to the known clinical status, but according to
the indication of the diagnostic procedure in clinical rou-
tine.
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The outlined development of CSF biomarkers for AD
can serve as a model which provides guidelines showing
what still has to be achieved in the development of bio-
markers for FTD. Additionally, a specific expression pat-
tern of tau proteins may serve in the future to discrimi-
nate different subtypes of neuropathology underlying the
clinical entity of FTD that may differ in prognosis and
response to treatment.
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